

10/089,819

-2-

A0000005/1-01-DRK

Amendments to the Claims:

1. (Currently Amended) A method for preventing or for treating chronic pain comprising administering to a patient in need of treatment an effective amount of a synergistic combination of a NK<sub>1</sub> receptor antagonist and a GABA analog.
2. (Original) A method of Claim 1 wherein the ratio of the GABA analog relative to the NK<sub>1</sub> receptor antagonist is from 50:1 to 1:1 expressed as parts by weight.
3. (Original) A method according to Claim 1 wherein the ratio of the GABA analog relative to the NK<sub>1</sub> receptor antagonist is 20:1 expressed as parts by weight
4. (Original) A method according to Claim 1 wherein the NK<sub>1</sub> receptor antagonist is [2-(1*H*-indol-yl)-1-methyl-l-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R\*,S\*)].
5. (Original) A method according to Claim 1 wherein the GABA analog is gabapentin.
6. (Original) A method according to Claim 1 wherein the GABA analog is pregabalin.
7. (Original) A method according to Claim 1 employing [2-(1*H*-indol-3-yl)-1-methyl-l-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester[R-(R\*,S\*)] and gabapentin.
8. (Original) A method according to Claim 1 employing [2-(1*H*-indol-3-yl)-1-methyl-l-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester[R-(R\*,S\*)] and pregabalin.
9. (Original) A method according to Claim 1 wherein the condition treated is selected from causalgia, neuropathic pain, diabetic neuropathy, post-surgery or traumatic neuropathy, postherpetic neuralgia, peripheral neuropathy, entrapment neuropathy,

10/089,819

-3-

A0000005/1-01-DRK

phantom limb and stump pain, neuropathy caused by alcohol abuse, HIV infection, multiple sclerosis, hypothyroidism or anticancer chemotherapy.

10. (Original) A pharmaceutical composition comprising synergistic effective amounts of a NK<sub>1</sub> receptor antagonist and a GABA analog.
11. (Original) A composition of Claim 10 wherein the ratio of the GABA analog relative to the NK<sub>1</sub> receptor antagonist is from 50:1 to 1:1 expressed as parts by weight.
12. (Original) A composition of Claim 10 wherein the ratio of the GABA analog relative to the NK<sub>1</sub> receptor antagonist is 20:1 expressed as parts by weight.
13. (Original) A composition of Claim 10 wherein the NK<sub>1</sub> receptor antagonist is [2-(1*H*-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R\*,S\*)].
14. (Original) A composition of Claim 10 wherein the GABA analog is gabapentin.
15. (Original) A composition of Claim 10 wherein the GABA analog is pregabalin.
16. (Original) A composition of Claim 10 employing [2-(1*H*-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R\*,S\*)] and gabapentin.
17. (Original) A composition of Claim 1 employing [2-(1*H*-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R\*,S\*)] and pregabalin.
18. (Cancel) The use of a composition comprising synergistic effective amounts of a NK<sub>1</sub> receptor antagonist and a GABA analog, or pharmaceutically acceptable salts thereof, for the preparation of a medicament useful for preventing or treating chronic pain.